Drug intelligence / Profile preview

V3G CH848 Pr-NP1

Development stage
Phase 1
Lead developer
National Institute of Allergy and Infectious Diseases
Modality
Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

V3G CH848 Pr-NP1 is an investigational prophylactic HIV-1 vaccine prime immunogen developed by the National Institute of Allergy and Infectious Diseases. It is a ferritin nanoparticle displaying eight copies of a native-like HIV-1 envelope trimer designed to initiate B-cell responses that can mature into V3-glycan-specific broadly neutralizing antibodies against HIV-1. It is being evaluated in a first-in-human Phase 1 prime-boost study in adults without HIV, with later boosting by the distinct mRNA-LNP immunogen V3G CH848 mRNA-Tr2. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05903339))

Other names
V3G + CH848 + Pr-NP1
02

Targets

gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)

Beyond the preview

Go deeper on V3G CH848 Pr-NP1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on V3G CH848 Pr-NP1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call